Full Length Research Paper
References
|
Aboud M, Elgalib A, Kulasegaram R, Dimian C, Duncan A, Wierzbicki AS, Peters BS (2007). Insulin resistance and HIV infection: a review. Int. J. Clin. Pract. 61:463-72. Crossref |
||||
|
Addy C, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW, Mantzoros CS (2003). Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 88:627-636. Crossref |
||||
|
Barbaro G (2003). HIV infection, highly active antiretroviral therapy and the cardiovascular system. Cardiovasc. Res. 60(1):87-95. Pubmed |
||||
|
Bedimo RJ (2008).Body-fat abnormalities in patients with HIV: progress and challenges. J. Int. Assoc. Physicians AIDS Care 7(6):292-305. Crossref |
||||
|
Bland MJ, DG Altman (2000). Statistics Notes: The odds ratio. BMJ 320:1468. Crossref |
||||
|
Boccara F (2008). Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors. AIDS 22(Suppl 3):19-26. Crossref |
||||
|
Brown TT, Cofrancesco J (2006). Metabolic Abnormalities in HIV-infected Patients: An Update. Curr. Infect. Dis. Rep. 8:497-504. Crossref |
||||
|
Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG (2012). PEARLS study team of the ACTG. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 9(8):e1001290. Crossref |
||||
|
Caron-Debarle M, Boccara F, Lagathu C, Antoine B, Cervera P, Bastard JP, Vigouroux C, Capeau J (2010a). Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations. Curr. Pharm. Des. 16(30):3352-60. Crossref |
||||
|
Caron-Debarle MC, Lagathu FB, Vigouroux C, Capeau J (2010b). HIV-associated lipodystrophy from fat injury to premature aging. Trends Mol. Med. 16(5):218-29. Crossref |
||||
|
Domingo P, Vidal F, Domingo JC, Veloso S, Sambeat MA, Torres F, Sirvent JJ, Vendrell J, Matias-Guiu X, Richart C (2005). Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis. Eur. J. Clin. Invest. 35(12):771-80. Crossref |
||||
|
Giralt M, Domingo P, Guallar JP, Rodriguez de la Concepción ML, Alegre M, Domingo JC, Villarroya F (2006). HIV-1 infection alters gene expression in adipose tissue which contributes to HIV-1 /HAART associated lipodystrophy. Antiviral Ther. 11:729-740. Pubmed |
||||
|
Gougeon ML, Pénicaud B, Fromenty LP, Viard JP, Capeau J (2004). Adipocytestargets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolicalterations Antiviral Ther. 9:161-177. Pubmed |
||||
|
Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J,Pierson RN (1989). Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am. J. Med. 86:27-31. Crossref |
||||
|
Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR (1992). Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74:1045-1052. Crossref |
||||
| Gupta SB, Pujari SN, Joshi SR, Patel AK (2006). AIDS Society of India GuidelineDevelopment Committee. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India. J. Assoc. Physicians 54:57-74. | ||||
|
Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, D'Agostino RB, Grinspoon S (2001). Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin. Infect. Dis. 32:130-139. Crossref |
||||
|
John M, Nolan D, Mallal S (2001). Antiretroviral therapy and the lipodystrophy syndrome. Antiviral Ther. 6:9-20. Pubmed |
||||
|
Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ (2005). Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med. 6(6):396-402. Crossref |
||||
|
Kanhai DA, Kranendonk ME, Uiterwaal CS, van der Graaf Y, Kappelle LJ, Visseren FL (2013). Adiponectin and incident coronary heart disease and stroke. A systematic review and meta-analysis of prospective studies. Obes. Rev. 14(7):555-67. Crossref |
||||
|
Kino T, Mirani M, Alesci S, Chrousos GP (2003a). AIDS-related lipodystrophy/insulin resistance syndrome. Horm. Metab. Res. 35(3):129-36. Crossref |
||||
|
Kino T, Chrousos GP (2003b). AIDS-related insulin resistance and lipodystrophy syndrome. Curr. Drug Targets Immun. Endocrinol. Metabol. Disord. 3(2):111-7. Crossref |
||||
|
Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R (2003). Adipocyte-derived hormone levels in HIV lipodystrophy. Antiviral Ther. 8:9-15. Pubmed |
||||
|
Lagathu C, Kim M, Maachi M, Vigouroux C, Cervera P, Capeau J, Caron M, Bastard JP (2005). HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie 87(1):65-71. Crossref |
||||
|
Lanzafame M, Faggian F, Lattuada E, Ramarli D, Concia E, Vento S (2003). Is there a role for TNF-alpha in HIV1-associated lipodystrophy? Eur. J. Clin. Investig. 33(8):735-6. Crossref |
||||
|
Maher B, Alfirevic A, Javier Vilar F, Wilkins EG, Park BK, Pirmohamed M (2002). TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 16:2013-2018. Crossref |
||||
|
Marzocchetti A, Schwarz J, Di Giambenedetto S, Colafigli M, Bracciale L, Fabbiani M, Fantoni M, Trecarichi E, Cauda R, De Luca A (2011). The effect of polymorphisms incandidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy. AIDS Res. Hum. Retroviruses 27(12):1299-309. Crossref |
||||
|
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting nplasma glucose and insulin concentrations in man". Diabetologia 28(7):412-9. Crossref |
||||
|
Mehendale SM, Bollinger RC, Kulkarni SS, Stallings RY, Brookmeyer RS, Kulkarni SV, Divekar AD, Gangakhedkar RR, Joshi SN, Risbud AR, Thakar MA, Mahajan BA, Kale VA, Ghate MV, Gadkari DA, Quinn TC, Paranjape RS (2002). Rapid disease progression in human immunodeficiency virus type 1-infected seroconverters in India. AIDS Res. Hum. Retroviruses 18(16):1175-9. Crossref |
||||
|
Mondal D, Larussa VF, Agrawal KC (2001). Synergistic antiadipogenic effects of HIV type 1 protease inhibitors with tumor necrosis factor alpha: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases. AIDS Res. Hum. Retroviruses 17(17):1569-84. Crossref |
||||
|
Nolan D (2003). Metabolic complications associated with HIV protease inhibitor therapy. Drugs 63(23):2555-74. Crossref |
||||
|
Ohashi K, Ouchi N, Matsuzawa Y (2012). Anti inflammatory and anti-atherogenic properties of adiponectin. Biochimie 94(10):2137-42. Crossref |
||||
|
Padmapriyadarshini C, Ramesh Kumar S, Terrin N, Narendran G, Menon PA, Ramachandran G, Subramanyan S, Venkatesan P, Wanke C, Swaminathan S (2011). Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily non-nucleoside reverse-transcriptase inhibitor-based anti-retroviral therapy in India. Clin. Infect. Dis. 52(4):540-6. Crossref |
||||
|
Parakh A, Dubey AP, Kumar A, Maheshwari A (2009) Lipodystrophy and metabolic complications of highly active antiretroviral therapy. Indian J. Pediatr. 76(10):1017-21. Crossref |
||||
|
Patel AK, Pujari S, Patel K, Patel J, Shah N, Patel B, Gupte N in native Indian patients: comparison of effectiveness in clinical cohort. J. Assoc. Physicians India 54:915-8. Pubmed |
||||
|
Pujari S (1998). Antiretrovirals in India. Issues Med. Ethics. 6(1):24-5. Pubmed |
||||
|
Pujari SN, Dravid A, Naik E, Patel KK, Dravid A, Patel JK, Mane AA, Bhagat S (2005). Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J. Acquir. Immun. Defic. Syndr. 39(2):199-202. Pubmed |
||||
|
Pujari SN, Patel AK, Naik E, Bhagat S, Tash K, Nadler JP, Sinnott JT (2004). Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. J. Acquir. Immun. Defic. Syndr. 37(5):1566-9. Crossref |
||||
|
Sankale JL, Tong Q, Hadigan CM, Tan G, Grinspoon SK, Kanki PJ, Hotamisligil GS (2006). Regulation of adiponectin in adipocytes upon exposure to HIV-1. HIV Med. 7(4):268-74. Crossref |
||||
|
Sethi JK, Hotamisligil GS (1999). The role of TNF alpha in adipocyte metabolism. Semin. Cell Dev. Biol. 10:19-29. Crossref |
||||
|
Sevastianova K, Sutinen J, Kannisto K, Hamsten A, Ristola M, Yki-Järvinen H (2008). Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. Am. J. Physiol. Endocrinol. Metab. 295(1):85-91. Crossref |
||||
|
Singh P, Bid HK, Francis A, Kumar S, Singh R, Ramalingam K, Thangaraj K, Konwar R (2011). Role of ethnic variations in TNF-α and TNF-β polymorphisms and risk of breast cancer in India. Breast Cancer Res. Treatment 126(3):739-747. Crossref |
||||
|
Stankov MV, Behrens GM (2010). Contribution of inflammation to fat redistribution and metabolic disturbances in HIV-1 infected patients. Curr. Pharm. Des. 16(30):3361-71. Crossref |
||||
|
Swaminathan S, Padmapriyadarsini C, Yoojin L, Sukumar B, Iliayas S, Karthipriya J, Sakthivel R, Gomathy P, Thomas BE, Mathew M, Wanke CA, Narayanan PR (2010). Nutritional supplementation in HIV-infected individuals in South India: a prospective interventional study. Clin. Infect. Dis. 51(1):51-7. Crossref |
||||
|
Tanwani LK, Mokshagundam SL (2003). Lipodystrophy, insulin resis-tance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection. South Med. J. 96(2):180-8. Crossref |
||||
|
Veloso S, Olona M, Peraire J, Viladés C, Pardo P, Domingo P, Asensi V, Broch M, Aguilar C, López-Dupla M, Aragonés G, Garcia-Pardo G, Sirvent JJ, Vendrell J, Richart C, Vidal F (2011). HIV Lipodystrophy relationship between TNF-α genetic variants and combination antiretroviral therapy-related lipodystrophy syndrome in HIV type 1-infected patients: a case-control study and a meta-analysis. AIDS Res. Hum. Retroviruses 27(2):143-52. Crossref |
||||
|
Vigano A, Aldrovandi GM, Giacomet V, Merlo M, Martelli L, Beretta S, Luraschi P, Rombolà G, Mora S (2005). Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with Efavirenz in HIV-infected children. Antivir. Ther. 10(8):917-24. Pubmed |
||||
|
Villarreal-Molina MT, Antuna-Puente B (2012). Adiponectin: anti-inflammatory and cardioprotective effects. Biochimie 94(10):2143-9. Crossref |
||||
|
Villarroya F, Domingo P, Giralt M. (2009). Drug-induced lipotoxicity: lipodystrophy associated with HIV-1 infection and antiretroviral treatment. Biochim. Biophys. Acta. 1(3):392-9. |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
